Form 4 for EBS Emergent BioSolutions Inc.
Accepted 2025-03-10 00:00:00 ET · period of report 2025-03-06 · accession 0001367644-25-000048 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-10 | 2025-03-06 | EBS | PAPA JOSEPH C | Pres, CEO, Dir | A - Grant | $0.00 | +282.5K | 282.5K | New | $0 |
| D | 2025-03-10 | 2025-03-06 | EBS | PAPA JOSEPH C | Pres, CEO, Dir | A - Grant | $0.00 | +282.5K | 1.03M | +38% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-06 | A | A | 282,500 | $0.00 | 282,500 | D | — | — | (F1) Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each performance stock unit represents a right to receive one share of common stock. The performance stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company and upon achievement with respect to Adjusted EBITDA for the 2025 fiscal year, as certified by the Compensation Committee following the performance period. |
| 2 | Derivative | Employee Stock Options (Right to Buy) | 2025-03-06 | A | A | 282,500 | $0.00 | 1,032,500 | D | $5.80 · — to 2032-03-05 | 282,500 Common Stock | (F2) Vests in three equal installments beginning on the day prior to the anniversary date of the grant. |